Lantheus (NASDAQ:LNTH) Stock Price Down 4.3% – What’s Next?

Lantheus Holdings, Inc. (NASDAQ:LNTH) shares fell 4.3% during mid-day trading on Tuesday . The stock traded as low as $110.24 and last traded at $110.54. 296,201 shares were traded during trading, a decline of 69% from the average session volume of 953,683 shares. The stock had previously closed at $115.45.

Analyst Ratings Changes

A number of research firms recently commented on LNTH. Redburn Atlantic assumed coverage on Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target for the company. JMP Securities cut their price target on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating for the company in a report on Thursday, August 1st. Leerink Partners increased their price target on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, July 11th. B. Riley boosted their price objective on shares of Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Finally, Truist Financial reduced their target price on Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a report on Thursday, August 1st. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $126.00.

Lantheus Stock Performance

The company has a market cap of $6.33 billion, a price-to-earnings ratio of 14.95 and a beta of 0.51. The company has a debt-to-equity ratio of 0.55, a quick ratio of 4.41 and a current ratio of 4.68. The company has a fifty day moving average of $108.04 and a two-hundred day moving average of $95.57.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported $1.48 EPS for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Lantheus had a return on equity of 48.36% and a net margin of 29.80%. The firm had revenue of $378.73 million for the quarter, compared to analyst estimates of $373.58 million. Equities research analysts anticipate that Lantheus Holdings, Inc. will post 5.99 EPS for the current year.

Insiders Place Their Bets

In related news, Director Gerard Ber sold 15,500 shares of the stock in a transaction on Monday, August 12th. The stock was sold at an average price of $96.48, for a total value of $1,495,440.00. Following the completion of the sale, the director now directly owns 21,221 shares in the company, valued at $2,047,402.08. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 2.10% of the company’s stock.

Hedge Funds Weigh In On Lantheus

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. lifted its stake in Lantheus by 2.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 31,629 shares of the medical equipment provider’s stock valued at $1,969,000 after buying an additional 741 shares during the period. Janney Montgomery Scott LLC lifted its position in shares of Lantheus by 10.0% during the 1st quarter. Janney Montgomery Scott LLC now owns 8,804 shares of the medical equipment provider’s stock valued at $548,000 after acquiring an additional 799 shares during the period. Fidelis Capital Partners LLC bought a new position in Lantheus during the first quarter worth $34,000. Nordea Investment Management AB grew its holdings in Lantheus by 42.6% in the first quarter. Nordea Investment Management AB now owns 47,322 shares of the medical equipment provider’s stock worth $2,932,000 after purchasing an additional 14,147 shares during the period. Finally, Daiwa Securities Group Inc. bought a new stake in Lantheus in the first quarter valued at $1,269,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.